公开(公告)号：US20250019374A1

公开(公告)日：2025-01-16

申请号：US18709214

申请日：2022-11-10

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Andrew Bogdan ,  Elliot P. Farney ,  Jennifer M. Frost ,  Philip R. Kym ,  Zhaoming Xiong ,  Naomi Anne Barton ,  Claire Anne Marie Cariou-Mumford ,  Christopher Patrick McMahon ,  Giuseppe Nano

IPC: C07D417/04 ,  A61K31/433 ,  A61K31/454 ,  C07D417/14

Abstract: The present invention provides for compounds of Formula (I) (I); wherein R2, X, and Z have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.

公开(公告)号：US20230019236A1

公开(公告)日：2023-01-19

申请号：US17807292

申请日：2022-06-16

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Elliot P. Farney ,  Reza Shiroodi ,  Zhaoming Xiong ,  Qingwei Zhang ,  Matthew J. O'Connor ,  Geoff T. Halvorsen ,  Hongyu Zhao ,  Christina Baumgartner ,  Jennifer M. Frost ,  Philip R. Kym ,  Jason R. Abbott ,  Andrew Bogdan ,  Christos Economou ,  Xueqing Wang

IPC: A61K31/433 ,  A61K39/395 ,  A61P35/00 ,  C07D417/10 ,  A61K31/5377 ,  C07D285/06

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：US20250042894A1

公开(公告)日：2025-02-06

申请号：US18709204

申请日：2022-11-10

Applicant: Calico Life Sciences LLC ,  AbbVie Inc.

Inventor： Andrew Bogdan ,  Christos Economou ,  Jennifer M. Frost ,  Philip R. Kym ,  Spencer O. Scholz ,  Zhaoming Xiong

IPC: C07D417/14 ,  A61K31/433 ,  C07D417/04

Abstract: The present invention provides for compounds of Formula (I) wherein R1, has any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.

公开(公告)号：US20160355482A1

公开(公告)日：2016-12-08

申请号：US15239554

申请日：2016-08-17

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC: C07D215/48 ,  C07D409/14 ,  C07D487/08 ,  C07D471/04 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 和其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2和R3如说明书中所定义，可用于治疗由电压门控钠通道（例如Nav1）预防或改善的病症或病症。 7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。

公开(公告)号：US20210070756A1

公开(公告)日：2021-03-11

申请号：US17099133

申请日：2020-11-16

Applicant: AbbVie Inc.

Inventor： Steven D. Fidanze ,  Dachun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: C07D471/22 ,  A61P15/16 ,  A61P31/18 ,  A61P13/12 ,  A61P35/00 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

公开(公告)号：US20190389861A1

公开(公告)日：2019-12-26

申请号：US16254124

申请日：2019-01-22

Applicant: AbbVie Inc.

Inventor： Steven D. Fidanze ,  Dachun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: C07D471/22 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

公开(公告)号：US09452986B2

公开(公告)日：2016-09-27

申请号：US14613579

申请日：2015-02-04

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC: C07D215/48 ,  C07D401/12 ,  C07D409/14 ,  C07D487/08 ,  C07D401/14 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

CPC classification number: C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20160039821A1

公开(公告)日：2016-02-11

申请号：US14774866

申请日：2014-03-12

Applicant: ABBVIE INC.

Inventor： Steven D. Fidanze ,  Dachun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: C07D471/22 ,  C07D471/16

CPC classification number: C07D471/22 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中R1，R2，R6，Y1，Y2，Y3，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其是有用的 作为治疗疾病和病症的药剂，包括炎性疾病，癌症和AIDS。 还提供了包含一种或多种式（I）化合物的药物组合物。

公开(公告)号：US08980879B2

公开(公告)日：2015-03-17

申请号：US14203651

申请日：2014-03-11

Applicant: AbbVie Inc.

Inventor： Dachun Liu ,  John Pratt ,  Le Wang ,  Lisa A. Hasvold ,  Andrew Bogdan

IPC: C07D471/04 ,  C07D487/04 ,  A61K31/407 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/18 ,  C07D471/16 ,  C07D471/12 ,  C07D471/22

CPC classification number: A61K31/55 ,  C07D471/12 ,  C07D471/16 ,  C07D471/22 ,  Y02A50/463

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中R1，R2，R6，Y1，Y2，A1，A2，A3和A4具有说明书中定义的任何值及其药学上可接受的盐，其可用作 治疗疾病和病症的药剂，包括炎性疾病，癌症和艾滋病。 还提供了包含一种或多种式（I）化合物的药物组合物。

公开(公告)号：US20210253551A1

公开(公告)日：2021-08-19

申请号：US17100045

申请日：2020-11-20

Applicant: AbbVie Inc.

Inventor： Andrew Bogdan ,  Steven Fidanze ,  Keith McDaniel ,  John Pratt ,  Le Wang

IPC: C07D401/12 ,  C07D213/64 ,  C07D401/04

Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, X1, X2, R2, R3, R4, R5, R6, and m have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).